Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2016 | Pages:
335 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Chronic Pain - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Chronic Pain - Pipeline Review, H2 2016', provides an overview of the Chronic Pain pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Pain and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Chronic Pain - The report reviews pipeline therapeutics for Chronic Pain by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Chronic Pain therapeutics and enlists all their major and minor projects - The report assesses Chronic Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Chronic Pain Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Chronic Pain - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Chronic Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 8 List of Figures 10 Introduction 11 Global Markets Direct Report Coverage 11 Chronic Pain Overview 12 Therapeutics Development 13 Pipeline Products for Chronic Pain - Overview 13 Pipeline Products for Chronic Pain - Comparative Analysis 14 Chronic Pain - Therapeutics under Development by Companies 15 Chronic Pain - Therapeutics under Investigation by Universities/Institutes 22 Chronic Pain - Pipeline Products Glance 23 Late Stage Products 23 Clinical Stage Products 24 Early Stage Products 25 Unknown Stage Products 26 Chronic Pain - Products under Development by Companies 27 Chronic Pain - Products under Investigation by Universities/Institutes 35 Chronic Pain - Companies Involved in Therapeutics Development 36 AbbVie Inc 36 Acadia Pharmaceuticals Inc. 37 Adynxx, Inc. 38 Allergan Plc 39 Amorsa Therapeutics Inc. 40 arGEN-X BV 41 Asana BioSciences, LLC 42 AskAt Inc. 43 Astraea Therapeutics, LLC 44 Axsome Therapeutics, Inc. 45 BioDelivery Sciences International, Inc. 46 Biogen Inc 47 Bionomics Limited 48 Camurus AB 49 Cara Therapeutics, Inc. 50 Centrexion Therapeutics Corp 51 ChironWells GmbH 52 Collegium Pharmaceutical, Inc. 53 Crinetics Pharmaceuticals, Inc. 54 Cyclenium Pharma, Inc. 55 Cytogel Pharma, LLC 56 Daewoong Pharmaceutical Co., Ltd. 57 Daiichi Sankyo Company, Limited 58 Dompe Farmaceutici S.p.A. 59 Echo Pharmaceuticals B.V. 60 Egalet Corporation 61 Eli Lilly and Company 62 Elite Pharmaceuticals, Inc. 63 Glenmark Pharmaceuticals Ltd. 64 Grunenthal GmbH 65 Heron Therapeutics, Inc. 66 INSYS Therapeutics, Inc. 67 Johnson & Johnson 68 Kareus Therapeutics, SA 69 KPI Therapeutics, Inc. 70 Kymab Limited 71 Laboratorios Del Dr. Esteve S.A. 72 Lohocla Research Corporation 73 Lpath, Inc. 74 MD Biosciences GmbH 75 Merck & Co., Inc. 76 Moberg Pharma AB 77 Mundipharma International Ltd 78 Nanomerics Ltd 79 Nektar Therapeutics 80 Neura Therapeutik, LLC 81 Orion Oyj 82 Pacira Pharmaceuticals, Inc. 83 Pain Therapeutics, Inc. 84 PeriphaGen, Inc. 85 Pfizer Inc. 86 Phosphagenics Limited 87 Prismic Pharmaceuticals, Inc. 88 Purdue Pharma LP 89 Relmada Therapeutics, Inc. 90 Ribomic Inc. 91 Sea4Us 92 Shulov Innovative Science Ltd. 93 Synactix Pharmaceuticals, Inc. 94 Syntrix Biosystems, Inc. 95 Teva Pharmaceutical Industries Ltd. 96 Therapix Biosciences Ltd. 97 Trevena, Inc. 98 Voyager Therapeutics, Inc. 99 Yooyoung Pharmaceutical Co., Ltd. 100 Zynerba Pharmaceuticals, Inc. 101 Chronic Pain - Therapeutics Assessment 102 Assessment by Monotherapy Products 102 Assessment by Combination Products 103 Assessment by Target 104 Assessment by Mechanism of Action 111 Assessment by Route of Administration 118 Assessment by Molecule Type 120 Drug Profiles 122 (celecoxib + tramadol hydrochloride) - Drug Profile 122 (hydrocodone bitartrate + palmidrol) - Drug Profile 124 (morphine sulfate + palmidrol) - Drug Profile 125 (naltrexone hydrochloride + oxycodone hydrochloride) SR - Drug Profile 126 (oxycodone hydrochloride + palmidrol) - Drug Profile 127 (palmidrol + pregabalin) - Drug Profile 128 A-200 - Drug Profile 129 AGN-XX - Drug Profile 130 AGN-YY - Drug Profile 131 AMS-520 - Drug Profile 132 ASN-008 - Drug Profile 133 AVLX-144 - Drug Profile 134 AXS-06 - Drug Profile 135 AYX-1 - Drug Profile 136 AYX-2 - Drug Profile 138 BBI-11008 - Drug Profile 139 bupivacaine - Drug Profile 140 bupivacaine hydrochloride - Drug Profile 142 buprenorphine hydrochloride - Drug Profile 144 buprenorphine hydrochloride depot - Drug Profile 146 buprenorphine hydrochloride ER - Drug Profile 147 buprenorphine hydrochloride long acting - Drug Profile 149 cebranopadol - Drug Profile 150 cetirizine hydrochloride + cromolyn sodium - Drug Profile 153 cetuximab - Drug Profile 154 CNTX-0290 - Drug Profile 160 CNV-3000164 - Drug Profile 161 CNV-3000223 - Drug Profile 162 CR-4056 - Drug Profile 163 CR-701 - Drug Profile 164 CRB-0089 - Drug Profile 165 Cyt-1010 - Drug Profile 166 dexmedetomidine hydrochloride - Drug Profile 168 DF-2593A - Drug Profile 170 difelikefalin - Drug Profile 171 dronabinol - Drug Profile 178 DS-1971 - Drug Profile 180 DWJ-208 - Drug Profile 181 ECP-1014 - Drug Profile 182 Egalet-003 - Drug Profile 183 fluticasone propionate - Drug Profile 184 FY-101C - Drug Profile 185 FY-103B - Drug Profile 186 GBR-900 - Drug Profile 187 Gene Therapy to Activate Mu Opioid Receptor for Chronic Pain - Drug Profile 188 grapiprant - Drug Profile 189 HPI-201 - Drug Profile 191 HS-731 - Drug Profile 192 hydrocodone bitartrate ER - Drug Profile 193 hydrocodone bitartrate ER - Drug Profile 196 hydrocodone bitartrate ER - Drug Profile 197 hydromorphone hydrochloride - Drug Profile 198 Kindolor - Drug Profile 199 KY-1017 - Drug Profile 200 L-779976 - Drug Profile 201 lacosamide - Drug Profile 202 LEVI-04 - Drug Profile 203 levorphanol tartrate ER - Drug Profile 204 Lpathomab - Drug Profile 206 MD-354 - Drug Profile 209 Monoclonal Antibodies for Chronic Pain - Drug Profile 210 Monoclonal Antibodies to Block Nav1.7 for Chronic Pain - Drug Profile 211 morphine sulfate ER - Drug Profile 212 MR-309 - Drug Profile 216 NET-END - Drug Profile 218 NKTR-181 - Drug Profile 219 NL-001 - Drug Profile 222 NL-002 - Drug Profile 223 NM-0127 - Drug Profile 224 Omnitram - Drug Profile 225 onabotulinumtoxin A - Drug Profile 226 OSX-300 - Drug Profile 231 OSX-300 Backups - Drug Profile 232 oxycodone hydrochloride ER - Drug Profile 233 oxycodone hydrochloride ER - Drug Profile 236 oxycodone hydrochloride ER - Drug Profile 237 oxymorphone hydrochloride - Drug Profile 239 oxymorphone hydrochloride ER - Drug Profile 240 PAC-CP - Drug Profile 241 palmidrol - Drug Profile 242 Peptide to Block Cav2.2 for CNS Disorders - Drug Profile 243 Peptides to Inhibit Ion Channel for Chronic Pain - Drug Profile 244 Peptides to Target TRPV1 for Pain and Itch - Drug Profile 245 PN-6047 - Drug Profile 246 PRC-062 - Drug Profile 247 Prostatic Acid Phosphatase - Drug Profile 248 PspTx-3 - Drug Profile 249 raxatrigine hydrochloride - Drug Profile 250 RBM-005 - Drug Profile 253 REL-1017 - Drug Profile 254 SAFit2 - Drug Profile 257 Small Molecule for Chronic Pain - Drug Profile 258 Small Molecule for Chronic Pain - Drug Profile 259 Small Molecule for Neuropathic Pain, Chronic Pain and Inflammatory Pain - Drug Profile 260 Small Molecule to Antagonize GPR-84 for Chronic Pain - Drug Profile 261 Small Molecule to Antagonize NMDA Receptor and Block Sodium Channels for CNS disorders - Drug Profile 262 Small Molecule to Block Nav1.9 Channel for Pain - Drug Profile 264 Small Molecule to Inhibit ASK-1 for Chronic Pain - Drug Profile 265 Small Molecule to Inhibit mPGES-1 for Chronic Pain - Drug Profile 266 Small Molecules for Chronic Wound Pain - Drug Profile 267 Small Molecules to Activate KCNQ2 and KCNQ3 Channels for Chronic Pain and CNS disorder - Drug Profile 268 Small Molecules to Agonize Cannabinoid Type 1 and Type 2 Receptors for Chronic Pain and Neuropathic Pain - Drug Profile 269 Small Molecules to Agonize CB2 for Chronic Pain and Migraine - Drug Profile 270 Small Molecules to Agonize Delta Opioid Receptor for Chronic Pain - Drug Profile 271 Small Molecules to Agonize NOP for Pain and Alcohol Addiction - Drug Profile 272 Small Molecules to Agonize SSTR2 and SSTR4 for Chronic Pain and Neuropathic Pain - Drug Profile 273 Small Molecules to Agonize SSTR4 for Neuropathic Pain and Chronic Pain - Drug Profile 274 Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Drug Profile 275 Small Molecules to Block Cav2.2 Channel for Chronic Pain - Drug Profile 276 Small Molecules to Block Cav2.2 Channel for Chronic Pain - Drug Profile 277 Small Molecules to Block HCN1 Channel for Chronic Neuropathic Pain - Drug Profile 278 Small Molecules to Block Nav 1.7 Channels for Chronic And Neuropathic Pain - Drug Profile 279 Small Molecules to Block TRPA1 and TRPV1 for Central Nervous System - Drug Profile 280 Small Molecules to Block TRPV1 for Chronic and Neuropathic Pain - Drug Profile 281 Small Molecules to Inhibit Cyclooxygenase 2 for Chronic Pain - Drug Profile 282 Small Molecules to Inhibit DAAO for Chronic Pain - Drug Profile 283 Small Molecules to Inhibit Sepiapterin Reductase for Neuropathic and Chronic Pain - Drug Profile 284 Small Molecules to Target Opioid Receptors for Chronic Pain - Drug Profile 285 SYN-003 - Drug Profile 286 Synthetic Peptides to Target Mu Opioid Receptor and Delta Opioid Receptor for Pain - Drug Profile 287 tanezumab - Drug Profile 288 tapentadol hydrochloride IR - Drug Profile 291 TRV-734 - Drug Profile 293 U-2902 - Drug Profile 295 UMB-425 - Drug Profile 297 Vaccine to Target MCP-1 for Chronic Prostatitis and Chronic Pelvic Pain - Drug Profile 298 VM-902A - Drug Profile 299 VYNAV-01 - Drug Profile 300 XT-101 - Drug Profile 301 YYC-301 - Drug Profile 302 ZEP-3 - Drug Profile 303 ZYN-001 - Drug Profile 304 Chronic Pain - Dormant Projects 305 Chronic Pain - Discontinued Products 314 Chronic Pain - Product Development Milestones 317 Featured News & Press Releases 317 Appendix 325 Methodology 325 Coverage 325 Secondary Research 325 Primary Research 325 Expert Panel Validation 325 Contact Us 325 Disclaimer 326
List of Tables
Number of Products under Development for Chronic Pain, H2 2016 22 Number of Products under Development for Chronic Pain - Comparative Analysis, H2 2016 23 Number of Products under Development by Companies, H2 2016 25 Number of Products under Development by Companies, H2 2016 (Contd..1) 26 Number of Products under Development by Companies, H2 2016 (Contd..2) 27 Number of Products under Development by Companies, H2 2016 (Contd..3) 28 Number of Products under Development by Companies, H2 2016 (Contd..4) 29 Number of Products under Development by Companies, H2 2016 (Contd..5) 30 Number of Products under Investigation by Universities/Institutes, H2 2016 31 Comparative Analysis by Late Stage Development, H2 2016 32 Comparative Analysis by Clinical Stage Development, H2 2016 33 Comparative Analysis by Early Stage Development, H2 2016 34 Comparative Analysis by Unknown Stage Development, H2 2016 35 Products under Development by Companies, H2 2016 36 Products under Development by Companies, H2 2016 (Contd..1) 37 Products under Development by Companies, H2 2016 (Contd..2) 38 Products under Development by Companies, H2 2016 (Contd..3) 39 Products under Development by Companies, H2 2016 (Contd..4) 40 Products under Development by Companies, H2 2016 (Contd..5) 41 Products under Development by Companies, H2 2016 (Contd..6) 42 Products under Development by Companies, H2 2016 (Contd..7) 43 Products under Investigation by Universities/Institutes, H2 2016 44 Chronic Pain - Pipeline by AbbVie Inc, H2 2016 45 Chronic Pain - Pipeline by Acadia Pharmaceuticals Inc., H2 2016 46 Chronic Pain - Pipeline by Adynxx, Inc., H2 2016 47 Chronic Pain - Pipeline by Allergan Plc, H2 2016 48 Chronic Pain - Pipeline by Amorsa Therapeutics Inc., H2 2016 49 Chronic Pain - Pipeline by arGEN-X BV, H2 2016 50 Chronic Pain - Pipeline by Asana BioSciences, LLC, H2 2016 51 Chronic Pain - Pipeline by AskAt Inc., H2 2016 52 Chronic Pain - Pipeline by Astraea Therapeutics, LLC, H2 2016 53 Chronic Pain - Pipeline by Axsome Therapeutics, Inc., H2 2016 54 Chronic Pain - Pipeline by BioDelivery Sciences International, Inc., H2 2016 55 Chronic Pain - Pipeline by Biogen Inc, H2 2016 56 Chronic Pain - Pipeline by Bionomics Limited, H2 2016 57 Chronic Pain - Pipeline by Camurus AB, H2 2016 58 Chronic Pain - Pipeline by Cara Therapeutics, Inc., H2 2016 59 Chronic Pain - Pipeline by Centrexion Therapeutics Corp, H2 2016 60 Chronic Pain - Pipeline by ChironWells GmbH, H2 2016 61 Chronic Pain - Pipeline by Collegium Pharmaceutical, Inc., H2 2016 62 Chronic Pain - Pipeline by Crinetics Pharmaceuticals, Inc., H2 2016 63 Chronic Pain - Pipeline by Cyclenium Pharma, Inc., H2 2016 64 Chronic Pain - Pipeline by Cytogel Pharma, LLC, H2 2016 65 Chronic Pain - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016 66 Chronic Pain - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 67 Chronic Pain - Pipeline by Dompe Farmaceutici S.p.A., H2 2016 68 Chronic Pain - Pipeline by Echo Pharmaceuticals B.V., H2 2016 69 Chronic Pain - Pipeline by Egalet Corporation, H2 2016 70 Chronic Pain - Pipeline by Eli Lilly and Company, H2 2016 71 Chronic Pain - Pipeline by Elite Pharmaceuticals, Inc., H2 2016 72 Chronic Pain - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016 73 Chronic Pain - Pipeline by Grunenthal GmbH, H2 2016 74 Chronic Pain - Pipeline by Heron Therapeutics, Inc., H2 2016 75 Chronic Pain - Pipeline by INSYS Therapeutics, Inc., H2 2016 76 Chronic Pain - Pipeline by Johnson & Johnson, H2 2016 77 Chronic Pain - Pipeline by Kareus Therapeutics, SA, H2 2016 78 Chronic Pain - Pipeline by KPI Therapeutics, Inc., H2 2016 79 Chronic Pain - Pipeline by Kymab Limited, H2 2016 80 Chronic Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H2 2016 81 Chronic Pain - Pipeline by Lohocla Research Corporation, H2 2016 82 Chronic Pain - Pipeline by Lpath, Inc., H2 2016 83 Chronic Pain - Pipeline by MD Biosciences GmbH, H2 2016 84 Chronic Pain - Pipeline by Merck & Co., Inc., H2 2016 85 Chronic Pain - Pipeline by Moberg Pharma AB, H2 2016 86 Chronic Pain - Pipeline by Mundipharma International Ltd, H2 2016 87 Chronic Pain - Pipeline by Nanomerics Ltd, H2 2016 88 Chronic Pain - Pipeline by Nektar Therapeutics, H2 2016 89 Chronic Pain - Pipeline by Neura Therapeutik, LLC, H2 2016 90 Chronic Pain - Pipeline by Orion Oyj, H2 2016 91 Chronic Pain - Pipeline by Pacira Pharmaceuticals, Inc., H2 2016 92 Chronic Pain - Pipeline by Pain Therapeutics, Inc., H2 2016 93 Chronic Pain - Pipeline by PeriphaGen, Inc., H2 2016 94 Chronic Pain - Pipeline by Pfizer Inc., H2 2016 95 Chronic Pain - Pipeline by Phosphagenics Limited, H2 2016 96 Chronic Pain - Pipeline by Prismic Pharmaceuticals, Inc., H2 2016 97 Chronic Pain - Pipeline by Purdue Pharma LP, H2 2016 98 Chronic Pain - Pipeline by Relmada Therapeutics, Inc., H2 2016 99 Chronic Pain - Pipeline by Ribomic Inc., H2 2016 100 Chronic Pain - Pipeline by Sea4Us, H2 2016 101 Chronic Pain - Pipeline by Shulov Innovative Science Ltd., H2 2016 102 Chronic Pain - Pipeline by Synactix Pharmaceuticals, Inc., H2 2016 103 Chronic Pain - Pipeline by Syntrix Biosystems, Inc., H2 2016 104 Chronic Pain - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016 105 Chronic Pain - Pipeline by Therapix Biosciences Ltd., H2 2016 106 Chronic Pain - Pipeline by Trevena, Inc., H2 2016 107 Chronic Pain - Pipeline by Voyager Therapeutics, Inc., H2 2016 108 Chronic Pain - Pipeline by Yooyoung Pharmaceutical Co., Ltd., H2 2016 109 Chronic Pain - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2016 110 Assessment by Monotherapy Products, H2 2016 111 Assessment by Combination Products, H2 2016 112 Number of Products by Stage and Target, H2 2016 114 Number of Products by Stage and Mechanism of Action, H2 2016 121 Number of Products by Stage and Route of Administration, H2 2016 128 Number of Products by Stage and Molecule Type, H2 2016 130 Chronic Pain - Dormant Projects, H2 2016 314 Chronic Pain - Dormant Projects (Contd..1), H2 2016 315 Chronic Pain - Dormant Projects (Contd..2), H2 2016 316 Chronic Pain - Dormant Projects (Contd..3), H2 2016 317 Chronic Pain - Dormant Projects (Contd..4), H2 2016 318 Chronic Pain - Dormant Projects (Contd..5), H2 2016 319 Chronic Pain - Dormant Projects (Contd..6), H2 2016 320 Chronic Pain - Dormant Projects (Contd..7), H2 2016 321 Chronic Pain - Dormant Projects (Contd..8), H2 2016 322 Chronic Pain - Discontinued Products, H2 2016 323 Chronic Pain - Discontinued Products (Contd..1), H2 2016 324 Chronic Pain - Discontinued Products (Contd..2), H2 2016 325
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
